IP Library Granted Patent US 11,478,471
Granted Patent B2
US 11,478,471 · App. 17/094,544 · Granted Oct 25, 2022

Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Inventor: Per Marin (Vastra Frolunda, SE)
Assignee: Strongbridge Dublin Limited
A61K31/496A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,478,471
App. No.
17/094,544
Granted
Oct 25, 2022
Kind
B2
Abstract

Pharmaceuticals compositions comprising the 2S,4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R,4S ketoconazole enantiomer are useful to reduce cortisol synthesis and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.

Claims (3)

1. A method for treating a disease or condition associated with elevated cortisol levels in a patient in need of such treatment, said method comprising administering a composition comprising a ketoconazole component to said patient, wherein at least 90% of the ketoconazole component is comprised of the 2S,4R ketoconazole enantiomer.

2. A method for treating a disease or condition associated with elevated cortisol levels in a patient in need of such treatment, said method comprising administering a composition comprising a ketoconazole component to said patient, wherein at least 95% of the ketoconazole component is comprised of the 2S,4R ketoconazole enantiomer.

3. A method for treating a disease or condition associated with elevated cortisol levels in a patient in need of such treatment, said method comprising administering a composition comprising a ketoconazole component to said patient, wherein at least 99% of the ketoconazole component is comprised of the 2S,4R ketoconazole enantiomer.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2025
From: STRONGBRIDGE DUBLIN LIMITED
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 071072/0969 →
SECURITY INTEREST Recorded Mar 5, 2024
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LTD.
To: HAYFIN SERVICES LLP
Reel/Frame 066647/0595 →
SECURITY INTEREST Recorded Mar 9, 2022
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LIMITED
To: HAYFIN SERVICES LLP
Reel/Frame 059552/0066 →